At present, the molecule is being studied in an ongoing phase I/II clinical trial (NCT04755244) to evaluate its efficacy in combination with the BCL2 inhibitor venetox and AZA, especially for patients with relapsed/refractory acute myeloid leukemia (R/R AML) who have not been treated or are not suitable for standard induction chemotherapy (86). Here, BCL2 is linked to acute myeloid leukemia.